Show simple item record

dc.contributor.authorMadariaga, Aen_US
dc.contributor.authorRustin, GJSen_US
dc.contributor.authorBuckanovich, RJen_US
dc.contributor.authorTrent, JCen_US
dc.contributor.authorOza, AMen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2019-06-27T11:59:12Z
dc.date.issued2019-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31099646en_US
dc.identifier.citationAm Soc Clin Oncol Educ Book, 2019, 39 pp. e152 - e166en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3280
dc.identifier.eissn1548-8756en_US
dc.identifier.doi10.1200/EDBK_238755en_US
dc.description.abstractEpithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70% of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the disease. Although this number has slowly improved, cure rates remain less than 50%. As such, maintenance therapy with the aim of preventing or delaying disease relapse and the goal of improving overall survival has been the subject of intense study. Numerous earlier studies with agents ranging from radioactive phosphorus to extended frontline therapy or to monthly taxol administration demonstrated encouraging improvements in progression-free survival (PFS) only to find, disappointingly, no benefit in overall survival. In addition, the PFS advantage of maintenance therapy was associated with disconcerting side effects such that maintenance therapy was not adapted as standard of care. Studies with bevacizumab and PARP inhibitors have demonstrated a PFS advantage with a manageable side-effect profile. However, an overall survival advantage remains unclear, and the use of these approaches thus remains controversial. Furthermore, in recurrent disease, the length of chemotherapy and benefits of extended chemotherapy is unclear. Thus, additional trials assessing maintenance strategies in ovarian and other gynecologic malignancies are needed.en_US
dc.format.extente152 - e166en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleWanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/EDBK_238755en_US
rioxxterms.licenseref.startdate2019-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAm Soc Clin Oncol Educ Booken_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.publication-statusPublisheden_US
pubs.volume39en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorRustin, Gordonen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/